Neuroreport · 2008 · 52 citations · 20 references
Life SciencesNeurobiologyNeuroscienceMolecular NeurobiologyMolecular NeuroscienceNeurochemistryGlutamatergic SignalingNeurodegenerative DiseasesNeurodegenerative DisordersNeurotransmissionParkinson DiseaseParkinsonian DisordersDopaminergic NeurodegenerationGlutamate NeurotransmissionNigrostriatal Dopamine PathwayParkinson Disease PathologyParkinsonian DegenerationPolyclonal AntibodiesProtein Expression LevelsWestern Blotting
Altered glutamate signaling is associated with Parkinson's disease. To study the involvement of the cystine/glutamate antiporter in the pathogenesis of Parkinson's disease, we developed new polyclonal antibodies recognizing xCT, the specific subunit of this antiporter. The striatal xCT protein expression level was investigated in a hemi-Parkinson rat model, using semiquantitative western blotting. We observed time-dependent changes after a unilateral 6-hydroxydopamine lesion of the nigrostriatal pathway with increased expression levels in the deafferented striatum after 3 weeks. Twelve weeks postlesion, expression levels returned to normal. These data suggest, for the first time, an involvement of the cystine/glutamate antiporter in determining the aberrant glutamate neurotransmission in the striatum of a parkinsonian brain.
20
The Origin and Neuronal Function of<i>In Vivo</i>Nonsynaptic Glutamate
David L. Baker, Zheng‐Xiong Xi, Hui Shen et al. · Journal of Neuroscience · 2002 · 583 citations · Full text